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OBJECTIVE: To observe patterns of antidepressant use
and concomitant psychotropics as an index of clinical
prescribing practice. METHODS: Among 1.6 million
members of Merck-Medco followed continuously be-
tween 1/1/96–12/31/98, we identified all patients (N 
42,510) who received a new antidepressant prescription
(defined as none within the prior 12 months) in 1997 (In-
dex AD). We observed the time between the use of other
concomitant psychotherapeutics (e.g. conventional anti-
psychotics (AP)/atypical antipsychotics (AP-A), benzodi-
azepine, anxiolytics (ANX)/buspirone (ANX-B), sedative/
hypnotics (SH) and zolipidem (SH-Z)) in the year prior
to or year after the index AD prescription. RESULTS:
14,792 (34.8%) AD patients were prescribed a concomi-
tant psychotherapeutic agent. All classes of concomitant
psychotherapeutics revealed a similar general pattern: a
steady increase in daily use in the year prior to an index
AD, a peak on the index AD date, and a tapering over the
next year. However, patients were more likely to receive
a conventional antipsychotic and anxiolytic prior to the
index AD, and an atypical antipsychotic and buspirone
after the index AD.
CONCLUSIONS: Whereas we hypothesized excessive
benzodiazepine and hypnotic usage pre- and post-index
AD, we noted lower than expected usage. We did not ex-
pect the pattern of increased atypical antipsychotic usage
on the same day or subsequent to an index AD. We spec-
ulate that continuing medical education of physicians
may be contributing to a decrease in the putative misuse
of benzodiazepines and hypnotics.
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Concomitant % of AD patients
Pre-Index 
AD (cumulative-1yr)
AP 2.28 .87
AP-A 2.36 .58
ANX 21.30 12.30
ANX-B 3.73 1.58
SH 5.73 2.98
SH-Z 8.96 4.25
Concomitant Same Day
Post-Index 
AD (cumulative-1 yr)
AP .30 1.12
AP-A .38 1.40
ANX 1.99 7.00
ANX-B .36 1.79
SH .37 2.37
SH-Z .75 3.97
BACKGROUND: The California Medicaid program
(Medi-Cal) added fluoxetine and paroxetine to its formu-
lary in May 1996. OBJECTIVES: This study evaluated
the impact of this policy change on the number of pa-
tients seeking treatment, treatment completion rates and
the cost of treating depressed patients. METHODS: All
patients with a recorded diagnosis of major depression
(MDD) between 09/01/1994 and 12/31/1997 were se-
lected from the Medi-Cal paid claims system. Completed
therapy required 180 days of uninterrupted therapy at an
adequate dose as estimated from drug claims. Multivari-
ate statistical models of treatment completion and direct
health care costs were estimated. RESULTS: The policy
change resulted in an immediate increase in the number
of new antidepressant drug therapy episodes initiated per
month (woodwork effect), but only for the newly added
drugs. The prior use profile of treated patients exhibited
a significant time trend toward higher prior use and com-
pleted therapy rates decreased for all products. Patients
treated initially with fluoxetine and sertraline were signif-
icantly more likely to complete therapy than TCA pa-
tients (odds ratios: 4.73 before change, 2.10 after for flu-
oxetine; 2.15 and 1.24 for sertaline, respectively).
Completion rates for paroxetine were not statistically
different from TCAs (odds ratios: 1.27, P  0.3147 be-
fore and 1.017, P  0.3943 after). Completed therapy
was associated with reductions in ambulatory care costs
in both periods. However, increased drug costs com-
pletely offset these savings after the formulary change.
CONCLUSION: The change in Medi-Cal formulary pol-
icy adding fluoxetine and paroxetine may have provided
new treatment options for more severely ill, refractory
patients that may have resulted in a modest increase in
costs.
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Osteoporosis affects over 28 million Americans, causing
over $13.8 billion in healthcare costs annually. Aging of
the population is expected to increase the national bur-
den of osteoporosis, though little is known about state
level impacts. In Florida, there is a large and growing at-
risk population (6.2 million age 45 and 2.7 million age
65). In 1998, there were 25,000, 4500, 1600 and
12,500 hip, vertebral, forearm/wrist and other fracture
hospitalizations, respectively. OBJECTIVE: To predict
the costs of osteoporosis in Florida over the next decade.
METHODS: Inpatient costs were estimated from Florida
hospital discharge data and primary and long-term care
costs were obtained from published national estimates.
Costs of osteoporosis for women age 50–100 were pre-
